Balance Pharmaceuticals

Balance Pharmaceuticals was a private biopharmaceutical company based in Santa Monica, California, dedicated to the development of therapies for metabolic diseases. The company's primary focus was on addressing the global obesity epidemic and related conditions like type 2 diabetes through optimized drug combinations. Its lead candidate, BPI-002, was a fixed-dose combination of naltrexone and bupropion that targeted the brain's reward system to reduce food cravings and appetite. By leveraging known compounds with established safety profiles, Balance Pharmaceuticals sought to provide effective and well-tolerated treatment options for chronic weight management. The company was founded by industry veteran Dennis Goldberg and progressed its lead programs through mid-stage clinical development before its dissolution in 2018.